Sarilumab COVID-19 Trial Results; Essure Adverse Events Updated

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

Thu, Apr 30, 3:18 AM (1 day ago)

to me

If you are having trouble viewing this email, click here.

MUST READS Sarilumab COVID-19 Trial to Include Only “Critical” Patients Following Results of Phase 2 Portion Lokelma Labeling Updated With Dosing for Hyperkalemia in Dialysis-Dependent ESRD Ajovy Now Available in Autoinjector Device for Migraine Prevention FDA Updates Essure Adverse Events Page to Include 2019 Reports Cemiplimab NSCLC Trial Stopped Early After Demonstrating Survival Benefit COVID-19 Resource Center Featured Content Collection and Use of Real-World Data Continues to Grow Around the World CME/CE Spotlight Are Your Patients Using the Most Effective Contraceptive Methods for Them? AMA PRA Category 1 Credit(s)TM CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME